LCM-Star Tablet is a combination pharmaceutical formulation containing Levocetirizine 5 mg and Montelukast 10 mg, designed for the management of allergic conditions and respiratory disorders. Levocetirizine, a third-generation non-sedative antihistamine, selectively inhibits peripheral H1 histamine receptors, thereby alleviating symptoms such as rhinorrhea, sneezing, itching, and urticaria associated with allergic rhinitis and chronic idiopathic urticaria. Montelukast, a leukotriene receptor antagonist, blocks cysteinyl leukotriene receptors (CysLT1), reducing bronchoconstriction, inflammation, and mucus production, which are pivotal in asthma pathophysiology and allergic rhinitis. The synergistic action of these agents provides comprehensive relief from allergic symptoms and improves respiratory function by targeting multiple inflammatory pathways. LCM-Star is indicated for the treatment of seasonal and perennial allergic rhinitis, chronic idiopathic urticaria, and as an adjunct therapy in asthma management to improve symptom control and reduce exacerbations. The combination is generally well-tolerated; common adverse effects may include headache, fatigue, and gastrointestinal disturbances. It is contraindicated in patients with known hypersensitivity to either component. Dosage and administration should be guided by a healthcare professional based on patient-specific factors. LCM-Star offers an effective therapeutic option for patients requiring dual-action antihistamine and leukotriene receptor antagonist therapy.